ESCMID Global is the annual congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (formerly ECCMID).
ESCMID Global 2026 took place in took place in Munich, Germany, between April 17 and 21.
The analyst attended industry-sponsored symposia as well as scientific sessions where key therapies were featured, the contents of which were analyzed to create this ESCMID Global 2026 Highlights report.
ESCMID Global 2026 took place in took place in Munich, Germany, between April 17 and 21.
The analyst attended industry-sponsored symposia as well as scientific sessions where key therapies were featured, the contents of which were analyzed to create this ESCMID Global 2026 Highlights report.
Report Scope
Indications, therapies, and companies discussed:
Respiratory Syncytial Virus (RSV)
- Zelicapavir - Enanta Pharmaceuticals
- Nirsevimab - AstraZeneca
Influenza
- mRNA-1010 - Moderna
- Secutrelvir - Shionogi & Co
Herpes Simplex Virus (HSV)
- Pritelivir - AiCuris
- Adibelivir (IM-250) - Innovative Molecules
Chikungunya Virus (CHIKV)
- EVT894 - Evotec
Hepatitis B (HBV)
- TherVacB - Helmholtz-Zentrum fur Umweltforschung
Fungal Infections
- Olorofim - F2G
- SCY-247 - Scynexis
Reasons to Buy
This powerpoint-based deliverable provides analysis on key presentations from the conference, and what they mean for your strategy, covering disease areas such as RSV, HSV, HBV, fungal infections, and more.Inside the report you’ll find:
- Emerging trends in prophylactic or therapeutic strategies for the management of viral and fungal infections
- Insights into the disease areas and key sponsors that took precedence at the conference
- Key takeaways from headline sessions and late-breaking data
- Clinical and commercial implications of notable presentations
Table of Contents
1. Introduction1.1. Table of Contents
1.2. Report Overview
1.3. Abbreviations
2. Conference Overview
2.1. Breakdown of presentations by presentation type
2.2. Top 10 drug mentions by presentation
2.3. Top 10 indications with drug mentions
2.4. Top sponsors by no. of presentations
3. Key Presentations
3.1. Respiratory Syncytial Virus (RSV)
3.1.1. Zelicapivir - Enanta Pharmaceuticals
3.1.2. Nirsevimab - AstraZeneca
3.2. Influenza
3.2.1. mRNA-1010 - Moderna
3.3. COVID-19
3.3.1. Secutrelvir - Shionogi & Co
3.4. Herpes Simplex Virus (HSV)
3.4.1. Pritelivir - AiCuris
3.4.2. Adibelivir (IM-250) - Innovative Molecules
3.5. Chikungunya Virus (CHIKV)
3.5.1. EVT894 - Evotec
3.6. Hepatitis B Virus (HBV)
3.6.1. TherVacB - Helmholtz-Zentrum fur Umweltforschung
3.7. Fungal Infections
3.7.1. Olorofim - F2G
3.7.2. SCY-247 - Scynexis
4. Appendix
4.1. About the Authors
4.2. About the Analyst
4.3. Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Enanta Pharmaceuticals
- AstraZeneca
- Moderna
- Shionogi
- AICuris
- Innovative Molecules
- Evotec
- Helmholtz-Zentrum fur Umweltforschung
- F2G
- Scynexis
